Advertisement
Advertisement
NCNA
NuCana plc - ADR
2.11
USDSponsored
+0.02
+0.96%
May 08, 15:58 UTC -4
Closed
After-Market
2.18
+0.07
+3.32%
NCNA Earnings Reports
Positive Surprise Ratio
NCNA beat 14 of 27 last estimates.
52%
Next Report
Date of Next Report
Jun 01, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q1 25 (Revenue/ EPS)
--
/--
NuCana plc - ADR earnings per share and revenue
On Mar 18, 2026, NCNA reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of -3.31 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.72% price change (close before vs. close after earnings).
Looking ahead to Q1 26, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Werewolf Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.29
Actual
-$0.28
Surprise
+3.68%
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
FAQ
What were NuCana plc - ADR's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, NuCana plc - ADR reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.
How did the market react to NuCana plc - ADR's Q4 2025 earnings?
The stock price moved down -1.72%, changed from $1.74 before the earnings release to $1.71 the day after.
When is NuCana plc - ADR expected to report next?
The next earning report is scheduled for Jun 01, 2026.
What are the forecasts for NuCana plc - ADR's next earnings report?
Based on --
analysts, NuCana plc - ADR is expected to report EPS of -- and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement